Join our daily newsletter At The Bell to receive exclusive market insights
The ASX200 finished off the first day of December down 0.2 of a percent – with all sectors, except energy, losing some ground.
In the Green
Retail conglomerate Premier Investments (ASX:PMV) gained 2.8 per cent today following its Annual General Meeting.
Premier has seven brands including Peter Alexander, Portmans, Dotti, Just Jeans, Jay Jay, Jacqui-E and Smiggle.
Management reported record sales during last week’s Black Friday sales event and forecasts earnings before interest and tax to be about $200 million for the half year to late January.
PMV closed at $25.11.
Medical software company 4DMedical (ASX:4DX) was up more than 1.5 per cent after holding a webinar update for shareholders.
The company reported $21.1 billion was spent in the US on respiratory diagnostics each year. 4DMedical has 4D lung scanning technology.
Management discussed the MOU signing announced this week with global health tech company Philips to commercialise 4DMedical’s XV Technology.
4DX closed trade at 97 cents.
Australian defence and space tech company, Electro Optic Systems (ASX:EOS), was up 11.56 per cent on lifting its revenue guidance for 2023 to between $210-$230 million.
This comes as a result of the group widening its product offering and its customer base in Australia, Western Europe and the Middle East.
EOS closed trade at 96.5 cents.
In the Red
Coles (ASX:COL) was down a per cent, despite the ACCC deciding not to oppose Coles’ planned acquisition of two milk processing plants from dairy processor Saputo, for $105 million.
The plants are in Erskine Park, NSW, and Laverton, VIC, close to Coles’ distribution centres.
Coles has had its milk processed by Saputo at the facilities, and, after the acquisition, will process Saputo’s milk there.
COL finished the day at $15.17.
NeuroScientific Biopharmaceuticals (ASX:NSB) has dipped about 15.5 per cent, following the resignation of chief executive officer Stephen Carter, effective at the end of the year.
The company is developing drugs for multiple neurodegenerative conditions. Mr Carter will continue to oversee preparations for the company’s upcoming Investigational New Drug (IND) submission to the US Food and Drug Administration (FDA) in the first quarter of the 2024 calendar year.
NSB closed the day at 6 cents.
And mineral exploration company Prospech (ASX:PRS) was down nearly 15 per cent after announcing a Share Purchase Plan to raise about $2 million will open on Tuesday.
Shares are offered at 3.1 cents– which is a 15 per cent discount to the volume-weighted average price (VWAP) and a 24 per cent discount to yesterday’s closing price.
PRS is hoping to use the funds to accelerate exploration at its Finland and Slovakia Rare Earth Elements projects.
PRS closed trade just above the raise price at 3.5 cents.
